CagriSema combo data looks promising, anyone tracking amylin analog stacks yet?

Question

Been digging into CagriSema since the dual-mechanism approach caught my attention. The idea of hitting both the amylin pathway and GLP-1 at once seems like it could move the needle more than just titrating sema higher, especially for people who plateau around the 15-18% loss mark. What interests me is the satiety angle from cagrilintide working through the area postrema rather than purely hypothalamic GLP-1 signaling. Sounds like it could help with the food noise that some folks still report even at therapeutic sema doses. For anyone who has actually run a cagrilintide-containing combo, how did the nausea compare to straight GLP-1 titration? I'm wondering if the side effect profile stacks linearly or if there's some kind of ceiling effect because the pathways are complementary rather than redundant. Also curious whether the appetite suppression felt qualitatively different, like more "fullness" versus just "not hungry." I know the trial numbers look strong but I want to hear from people actually experimenting before I get too excited about the theoretical ceiling.

runner_aaron · Accepted Answer

Honestly I've only played around with cagrilintide on its own for a short stretch, so I can't speak to the combo directly. On its own though the nausea was rougher than sema for me, especially the first week, but it did feel different for satiety. More like actual fullness rather than just not wanting food, which I reckon is the amylin piece doing its thing through different receptors. What I want to know is whether running cagrilintide lower than the trial dose keeps the fullness benefit but drops the nausea, or if that's wishful thinking. Did anyone titrate slower than the 2.4mg weekly step-up and notice the side effects actually calmed down without losing the appetite quality?

weekendnate · Answer

You're right that the receptor overlap is the weak point in my hypothesis, honestly. I was mostly spitballing about a ceiling because the area postrema thing made it sound cleaner than it probably is in practice. No, I didn't titrate slower on this one, I bumped every two weeks like the protocol suggested, and by week three the nausea was rough enough that I pulled back to the previous dose for an extra week before going up. Felt like the right call at the time but I don't have a slower-titration arm to compare against, so that's just my gut, not data. If you had someone in front of you who was hitting that nausea wall, would you personally recommend spreading the escalation out longer, or is that just delaying the inevitable?

weekendnate · Answer

Yeah that fullness vs just-not-craving distinction is exactly what stood out to me too, and honestly the main reason I'm interested in stacking it rather than just pushing sema harder. Reasonable question on the lower dose, my guess is you'd keep a decent chunk of the satiety signal since amylin receptor activation tends to have a flatter dose-response than GLP-1, but the nausea would probably still show up in the first couple weeks because that's more of an acute area postrema thing. Did your solo run settle down after the first week or did it stay rough through the whole stretch?

avery_c · Answer

That tracks with what I keep hearing anecdotally about the nausea, and it's interesting that the satiety felt qualitatively different to you rather than just stronger, which would fit the area postrema mechanism they keep talking about in the literature. On your titration question, I haven't seen data showing a lower ceiling where you keep the fullness and lose the sickness, and I'm kinda skeptical there's a clean dose-response split like that since the receptors driving nausea and satiety probably overlap a lot. Curious if you tried going slower in practice or if you were still working up to 2.4 when you stopped?

CagriSema combo data looks promising, anyone tracking amylin analog stacks yet?

Comments